(USD) | Dec 2023 | Q/Q |
---|---|---|
Revenue | 149.8MM | +87% |
Gross Profit | 118.3MM | +86% |
Cost Of Revenue | 31.5MM | +89% |
Operating Income | 13.2MM | - |
Operating Expenses | 105.1MM | - |
Net Income | 10.5MM | - |
R&D | 21.2MM | +85% |
G&A | 105.1MM | +83% |
Marketing | 49MM | +84% |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Staar Surgical (STAA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Staar Surgical preannounced strong first-quarter sales on Thursday, helping Staar stock retake its 200-day line and hit a seven-month high.
Thursday, STAAR Surgical Company (NASDAQ:STAA) reported preliminary net sales for the first quarter of 2024 of more than $77 million versus the consensus of $72.13 million, with U.S. ICL sales expected to be $5 million for the quarter. This represents the company’s highest quarterly ICL sales in the U.S. since the company obtained U.S. FDA approval for the EVO ICL in March 2022. “STAAR is off to a solid start in 2024 as illustrated by our preliminary first quarter results, including a record qua
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...
LAKE FOREST, Calif., April 04, 2024--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced preliminary net sales for the first quarter ended March 29, 2024, are expected to be in excess of $77 million with U.S. ICL sales expected to be $5 million for the quarter. This represents the Company’s highest quarterly ICL sales in the U.S. since the Company
LAKE FOREST, Calif., April 02, 2024--STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL) for myopia, astigmatism and presbyopia, comes to the American Society of Cataract and Refractive Surgery Annual Meeting (ASCRS) in Boston from April 5-8, 2024, fresh off the achievement of a new commercial milestone: three million lenses sold. Furthering the momentum behind its flagship product, EVO ICL, the company
Nvidia (NASDAQ:NVDA) is massive. It is the third-largest company by market capitalization. In a little more than one year, the artificial intelligence (AI) chipmaker grew from a puny $364 million valuation to become worth almost $2.4 trillion! Barring penny stocks, that could be one of the fastest meltups in stock market history. As consider, Nvidia’s market cap, investors need to consider other AI stocks. But size isn’t everything. Not that you would know it by watching NVDA stock, but companie
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that more than three million ICLs have been sold globally.1
STAAR Surgical Company ( NASDAQ:STAA ) shareholders should be happy to see the share price up 25% in the last month...
West Pharmaceutical (WST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.